Latest News & Features
Refine Search
article
 Many jurisdictions provide patent term extensions or Supplementary Protection Certificates in recognition of the fact that the time taken to achieve regulatory approval for patented products can often delay their release into the market.   30 June 2022 
Big Pharma
 Pfizer is facing a lawsuit centring on its COVID-19 antiviral, Paxlovid, after Enanta Pharmaceuticals filed a complaint citing patent infringement.   28 June 2022 
Americas
 Drugmaker Genus Lifesciences and pharmaceutical company Mallinckrodt have agreed to settle their trade secret dispute related to a cocaine hydrochloride formulation.   28 June 2022 
Big Pharma
 India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film.   27 June 2022 
article
 The COVID-19 IP agreement promises to enable developing countries more autonomy to produce and distribute vaccines, but it has attracted many critics, finds Sarah Speight.   23 June 2022 
Big Pharma
 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent  Trial and Appeal Board (PTAB) when declining to review a patent’s validity.   23 June 2022 
Big Pharma
 The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug.   23 June 2022 
Big Pharma
 The England and Wales Patent Court affirmed its power to grant injunctions for pre-grant patents—but not for Novartis, explains Azadeh Vahdat of EIP.   21 June 2022 
Big Pharma
 The European Commission has opened an antitrust investigation to assess whether Switzerland-headquartered Vifor Pharma has engaged in anticompetitive conduct.   21 June 2022 
Medtech
 Ohio-based Cleveland Medical Devices (CleveMed) has accused ResMed of infringing patents through the sale of devices and software for the testing and treatment of sleep-disordered breathing or apnea.   21 June 2022 

